Risks
4 risks
Risk Intelligence
US pricing pressure and tariff uncertainty
View Risks →Alkem Laboratories Limited — Q4 FY25
Alkem Laboratories reported Q4 FY25 revenue of INR 3,144 crore, up 7.1% YoY, driven by domestic growth of 8.1% and international growth of 7.2%.
bullish
medium
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Alkem Laboratories reported Q4 FY25 revenue of INR 3,144 crore, up 7.1% YoY, driven by domestic growth of 8.1% and international growth of 7.2%. PAT grew 4.2% to INR 306 crore. For FY25, EBITDA margin expanded to 19.4% from 17.7% in FY24, aided by operational efficiencies. Management guided for stable EBITDA margins of ~19.5% in FY26, with R&D spend rising to ~5% of revenue. The US business is expected to deliver mid-single-digit growth, while domestic should outperform IPM by 100 bps. Key risks include US pricing pressure and potential operating losses of INR 100-125 crore from new CDMO and medtech ventures.
अल्केम लैबोरेटरीज ने चौथी तिमाही (जनवरी-मार्च 2025) में 3,144 करोड़ रुपये की कमाई की, जो पिछले साल से 7.1% ज्यादा है। भारत में बिक्री 8.1% और विदेश में 7.2% बढ़ी। मुनाफा 4.2% बढ़कर 306 करोड़ रुपये हुआ। पूरे साल में कंपनी ने खर्चों पर काबू रखते हुए मुनाफे की दर (EBITDA) 17.7% से बढ़ाकर 19.4% कर ली। अगले साल यह दर 19.5% के आसपास रहने का अनुमान है, लेकिन रिसर्च पर खर्च बढ़कर कमाई का 5% हो जाएगा। अमेरिका में धीमी बढ़त होगी, जबकि भारत में बाजार से 1% ज्यादा तेजी रहेगी। जोखिम: अमेरिका में कीमतों का दबाव और नए कारोबारों (CDMO, मेडटेक) से 100-125 करोड़ रुपये का शुरुआती घाटा।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
India Business Growth (Q4)
8.1%
+8.1% YoY
Domestic revenue grew 8.1% YoY to INR 2,136 crore, driven by strong execution and targeted initiatives.
Volume Growth vs IPM (FY25)
2.1%
+90 bps vs IPM
Alkem's volume growth of 2.1% outperformed the Indian pharma market's 1.2% volume growth.
Cash Balance
INR 46.2B
N/A
Cash and cash equivalents stood at INR 46.2 billion as of March 31, 2025, providing strong liquidity.
Engine CDMO Revenue (FY25)
INR 290 Cr
N/A
Engine business (including CDMO) generated INR 290 crore revenue in FY25, with CDMO sales starting Q2 FY26.
What Changed vs Last Quarter
NEW
US business mid-single-digit growth in FY26
US revenue is expected to grow at a mid-single-digit rate in FY26, driven by 5-6 new product launches and improved supply.
NEW
Domestic business to outperform IPM by 100 bps in FY26
India business is expected to grow at least 100 basis points above the IPM growth rate of 7-8%.
NEW
CapEx of INR 700-750 crore in FY26
Capital expenditure for FY26 is guided at INR 700-750 crore, including ~INR 200 crore for the Engine CDMO plant and routine maintenance.
UPDATED
EBITDA margin guidance of ~19.5% for FY26
Management expects EBITDA margins to remain stable at around 19.5% in FY26, supported by operating leverage and despite higher R&D investments.
DROPPED
Domestic business to grow in line with IPM (~7%) for FY25
Q4 implied growth of ~9.5-10% driven by strong secondary optics and low base.
DROPPED
US business expected to be flat YoY in Q4
Improved from -22% in Q2 to -7% in Q3; supply normalization should lead to neutral growth by Q4.
DROPPED
Semaglutide launch in first wave in India
Alkem has developed its own product, filed with regulator, and plans to be among the first to launch.
NEW RISK
US pricing pressure and tariff uncertainty
Continued price erosion in the US generics market and potential tariffs could impact US business growth and margins.
NEW RISK
Operating losses from new ventures
CDMO and medtech businesses are expected to incur combined operating losses of INR 100-125 crore in FY26, weighing on profitability.
NEW RISK
Tax rate increase post FY26
Tax rate is expected to rise to 35-37% from FY27 as MAT credit is utilized, significantly impacting net profit.
NEW RISK
Acute business seasonality and NLEM headwinds
Domestic acute business remains vulnerable to seasonal fluctuations and price control under NLEM, which could limit growth.
RISK GONE
US price erosion continues at mid-single digit
Price erosion in US generics is ~5% (2.5% on NRV basis) and expected to persist, pressuring US revenue growth.
RISK GONE
Acute therapy slowdown in India
India acute market growth slowed to 5.7% in Q3; Alkem's trade generics business (20% of domestic) was flat due to competition and pricing pressure.
RISK GONE
Chile currency and tender loss impact
Chile business declined ~30% due to exiting a low-priced tender and Chilean peso depreciation; recovery uncertain.
RISK GONE
Pen G price increase may pressure margins
Pen G prices rose 20-25% in last two months; if sustained, could impact input costs for Alkem's penicillin-based products.
🤫 Topics management stopped discussing
Mentioned in Q2 FY24, Q4 FY24
Q4 had INR 30 crore in service-level penalties due to supply issues; if not resolved, could impact US margins.
Mentioned in Q1 FY25, Q3 FY25
Q4 implied growth of ~9.5-10% driven by strong secondary optics and low base.
Mentioned in Q2 FY25, Q4 FY24
Management maintains full-year domestic growth guidance of 8-9%, with Q4 expected to be particularly strong.
Mentioned in Q2 FY25, Q3 FY24
Full-year EBITDA margin expected to be 18.5-19%, driven by cost controls and product mix improvement.
Mentioned in Q2 FY24, Q3 FY25
Pen G prices rose 20-25% in last two months; if sustained, could impact input costs for Alkem's penicillin-based products.
Fast read
Guidance and risk preview
Management expects EBITDA margins to remain stable at around 19.5% in FY26, supported by operating leverage and despite higher R&D investments.
Continued price erosion in the US generics market and potential tariffs could impact US business growth and margins.
View Risks →